Proactive Investors - Run By Investors For Investors

Kazia Therapeutics releases new safety data to assist in brain cancer treatments

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment. 
 
Garner said the superior results from the ongoing study of GDC-0084 in newly diagnosed glioblastoma patients was an important milestone for the company.
 
He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.
 
Meet Cardinal Resources Ltd and Legend Mining Ltd at our event, Melbourne , 16 July 2019. Register here »
View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use